ArticleNPJ primary care respiratory medicine2026
Hospital follow-up adherence among screen-positive lung cancer utilizing a mobile LDCT in community in Hainan, China: a prospective cohort study.
Article in NPJ primary care respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChina has the highest global disease burden for both lung cancer and tuberculosis (TB). Mobile low-dose computed tomography (LDCT) screening offers dual detection of early-stage lung malignancies and active TB radiographic manifestations. However, evidence regarding community-based post-screening compliance remains inadequate. This study aimed to evaluate hospital follow-up adherence and its associated factors among individuals who screened positive for lung cancer or TB in a community-based, non-risk-based LDCT screening program.
methodsA prospective cohort study was conducted in Dongfang, Hainan Province, from June to September 2024. Permanent residents aged ≥40 years were enrolled in a community-based, non-risk-stratified mobile LDCT screening program. At the time of screening, participants completed a structured questionnaire to capture demographic characteristics, risk factors, and health status. Screening images were interpreted according to established guidelines; individuals with findings indicative of Lung-RADS category 4 (4 A, 4B, 4X) or suspected active pulmonary TB were considered screen-positive. The primary outcome, adherence to hospital-based diagnostic follow-up within six months, was objectively assessed by linking screening records to the provincial medical insurance claims database. Multivariable logistic regression was used to identify factors associated with adherence, stratified by screening finding.
resultsAmong 22,933 participants (14,134 female and 8799 men), 547 (2.4%) had LDCT findings classified as Lung-RADS 4 and 653 (2.9%) displayed radiological features compatible with TB. Diagnostic follow-up within six months was completed by 303/547 lung-cancer suspects (55.4%) and 336/653 pulmonary TB suspects (51.5%). Among adherent individuals, 98 lung cancers (32.3%) and 95 active pulmonary TB cases (28.3%) were confirmed. In the lung-cancer cohort, respiratory symptoms increased the likelihood of follow-up (adjusted odds ratio [aOR] 2.47, 95% CI 1.13-5.41), whereas retired status decreased it (aOR 0.52, 0.32-0.85). In the pulmonary TB cohort, female sex was positively associated with adherence (aOR 1.39, 1.02-1.90), while formal employment was negatively associated (aOR 0.53, 0.31 - 0.90).
conclusionsThis study highlights the need for targeted interventions to optimize diagnostic follow-up and maximize the clinical and public health impact of integrated lung cancer-TB screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.